ITHACA: A phase 2, randomized, single-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of the complement C3 inhibitor, AMY-101, in COVID-19 patients with acute respiratory distress syndrome (ARDS)
Latest Information Update: 20 Feb 2023
At a glance
- Drugs AMY 101 (Primary)
- Indications SARS-CoV-2 acute respiratory disease
- Focus Therapeutic Use
- Acronyms ITHACA
- Sponsors Amyndas Pharmaceuticals
- 24 Oct 2021 Status changed from recruiting to discontinued.
- 29 Oct 2020 New trial record